Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Leucine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.82 |
| ▸ | SLC1A3 | P43003 | 7/20 | 0.63 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.63 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.54 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.47 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.47 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.46 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.46 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.45 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.45 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.43 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.43 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL11046762 | 1.00 | SLC7A5 (0.82) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| D-Leucine SCHEMBL18114536 | 1.00 | SLC7A5 (0.82) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL4639771 | 1.00 | SLC7A5 (0.82) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL625031 | 1.00 | SLC7A5 (0.82) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL2154089 | 1.00 | SLC7A5 (0.82) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| D-Leucine SCHEMBL1537345 | 1.00 | SLC7A5 (0.82) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL4664449 | 0.96 | SLC7A5 (0.75) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL4946381 | 0.96 | SLC7A5 (0.75) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL3049775 | 0.96 | SLC7A5 (0.75) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL4394541 | 0.96 | SLC7A5 (0.75) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4340592-A | OLICOPEPTIDES FOR DIETARY PURPOSES | ADIBI SIAMAK A | 1982-07-20 | — | — | US | claimed |
| US-20240042063-A1 | LINKED AND OTHER pH-TRIGGERED COMPOUNDS | UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES | 2024-02-08 | — | — | US | disclosed |
| EP-4211255-A1 | METHODS FOR BINDING SITE IDENTIFICATION USING HYDROGEN EXCHANGE MASS SPECTROMETRY | Regeneron Pharmaceuticals, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20220403452-A1 | SYSTEMS AND METHODS FOR BARCODING CELLS AND CELL BEADS | 10X GENOMICS INC (US) | 2022-12-22 | — | — | US | disclosed |
| EP-4025709-A1 | SYSTEMS AND METHODS FOR BARCODING CELLS AND CELL BEADS | 10X Genomics, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| WO-2021046475-A1 | SYSTEMS AND METHODS FOR BARCODING CELLS AND CELL BEADS | 10X GENOMICS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| EP-3634498-A1 | LINKED AND OTHER PH-TRIGGERED COMPOUNDS | Rhode Island Council on Postsecondary Education (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20180369425-A1 | LINKED AND OTHER pH-TRIGGERED COMPOUNDS | UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES | 2018-12-27 | — | — | US | disclosed |
| WO-2018227132-A1 | LINKED AND OTHER PH-TRIGGERED COMPOUNDS | RHODE ISLAND COUNCIL ON POSTSECONDARY EDUCATION (US) | 2018-12-13 | — | — | WO | disclosed |
| EP-2683391-B1 | FILAMENTOUS BACTERIOPHAGE FOR USE IN THE TREATMENT OF NEURODEGENERATIVE TAUOPATHY | UNIV RAMOT (IL) | 2015-05-06 | — | — | EP | disclosed |
| WO-2002072619-A1 | INTEGRIN αIIbβ3 ACTIVATING PEPTIDES AND THEIR USE | CTT CANCER TARGETING TECHNOLOGIES OY (FI) | 2002-09-19 | — | — | WO | disclosed |
| US-5876969-A | FUSION POLYPEPTIDE OF THERAPEUTIC POLYPEPTIDES ATTATCHED TO C-AND N-TERMINALS OF HUMAN SERUM ALBUMIN; FOR HIGH PLASMA STABILITY, MINIMIZATION OF DOSAGE, SIDE EFFECT REDUCTION | NOVOZYMES BIOPHARMA DK A/S (DK) | 1999-03-02 | — | — | US | disclosed |
| US-5665863-A | COUPLED TO ALBUMIN; GENETIC ENGINEERING | RHONE-POULENC RORER S.A. (FR) | 1997-09-09 | — | — | US | disclosed |
| EP-0625199-A1 | ANTITHROMBOTIC POLYPEPTIDES AS ANTAGONISTS OF THE BINDING OF VWF TO PLATELETS OR TO SUBENDOTHELIUM | Aventis Pharma S.A. (FR) | 1994-11-23 | — | — | EP | disclosed |
| EP-0624200-A1 | NEW POLYPEPTIDES HAVING GRANULOCYTE COLONY STIMULATING ACTIVITY, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID POLYPEPTIDES | Aventis Pharma S.A. (FR) | 1994-11-17 | — | — | EP | disclosed |
| EP-0624195-A1 | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAID POLYPEPTIDES | Aventis Pharma S.A. (FR) | 1994-11-17 | — | — | EP | disclosed |
| WO-1993015211-A1 | NEW POLYPEPTIDES HAVING GRANULOCYTE COLONY STIMULATING ACTIVITY, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID POLYPEPTIDES | RHONE-POULENC RORER S.A. (FR) | 1993-08-05 | — | — | WO | disclosed |
| WO-1993015199-A1 | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAID POLYPEPTIDES | RHONE-POULENC RORER S.A. (FR) | 1993-08-05 | — | — | WO | disclosed |
| WO-1993015200-A1 | ANTITHROMBOTIC POLYPEPTIDES AS ANTAGONISTS OF THE BINDING OF VWF TO PLATELETS OR TO SUBENDOTHELIUM | RHONE-POULENC RORER S.A. (FR) | 1993-08-05 | — | — | WO | disclosed |
| US-4340592-A | OLICOPEPTIDES FOR DIETARY PURPOSES | ADIBI SIAMAK A | 1982-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240042063-A1 | LINKED AND OTHER pH-TRIGGERED COMPOUNDS | LIPA, PHOSPHO1, NGLY1 | SLC7A5 844/4885SLC1A3 2292/4885SLC1A2 3348/4885 |
| US-20180369425-A1 | LINKED AND OTHER pH-TRIGGERED COMPOUNDS | LIPA, PHOSPHO1, NGLY1 | SLC7A5 844/4885SLC1A3 2292/4885SLC1A2 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.